Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Inclusion Criteria:

- Pathologically documented EBV antigen positive lymphoproliferative disease, lymphoma,
or other EBV-associated malignancy OR

- Severely immunocompromised patients who develop blood levels of EBV DNA exceeding 500
copies/ml DNA, and are therefore at high risk for developing an EBV LPD

It is expected that five types of patients afflicted with EBV-associated lymphomas or
lymphoproliferative diseases will be referred and will consent to participate in this
trial. These are:

1. Patients developing or at risk for EBV lymphomas or lymphoproliferative disorders
following an allogeneic marrow transplant.

2. Patients developing or at risk for EBV lymphomas or lymphoproliferative disorders
following an allogeneic organ transplant.

3. Patients with AIDS developing EBV lymphomas or lymphoproliferative diseases as a
consequence of the profound acquired immunodeficiency induced by HIV.

4. Patients who develop EBV lymphomas or lymphoproliferative diseases as a consequence of
profound immunodeficiencies associated with a congenital immune deficit or acquired as
a sequela of anti-neoplastic or immunosuppressive therapy.

5. Patients who develop other EBV-associated malignancies without pre-existing immune
deficiency, including: EBV+ Hodgkin's and Non- Hodgkin's disease, EBV+ nasopharyngeal
carcinoma, EBV+ hemophagocytic lymphohistiocytosis, or EBV+ leiomyosarcoma.

Exclusion Criteria:

The following patients will be excluded from this study:

- Moribund patients who, by virtue of heart, kidney, liver, lung, or neurologic
dysfunction not related to lymphoma, are unlikely to survive the 6-8 weeks required
for in vitro generation and expansion of the EBV-specific T cells to be used for
therapy and the subsequent 3 weeks required to achieve an initial assessment of the
effects of infusions of EBV-specific T cells.

- Pregnancy does not constitute a contraindication to infusions of EBV-specific T cells.